Circuit-specific gene therapy reverses core symptoms in a primate Parkinson's disease model

Cell. 2023 Nov 22;186(24):5394-5410.e18. doi: 10.1016/j.cell.2023.10.004. Epub 2023 Nov 2.

Abstract

Parkinson's disease (PD) is a debilitating neurodegenerative disorder. Its symptoms are typically treated with levodopa or dopamine receptor agonists, but its action lacks specificity due to the wide distribution of dopamine receptors in the central nervous system and periphery. Here, we report the development of a gene therapy strategy to selectively manipulate PD-affected circuitry. Targeting striatal D1 medium spiny neurons (MSNs), whose activity is chronically suppressed in PD, we engineered a therapeutic strategy comprised of a highly efficient retrograde adeno-associated virus (AAV), promoter elements with strong D1-MSN activity, and a chemogenetic effector to enable precise D1-MSN activation after systemic ligand administration. Application of this therapeutic approach rescues locomotion, tremor, and motor skill defects in both mouse and primate models of PD, supporting the feasibility of targeted circuit modulation tools for the treatment of PD in humans.

Keywords: Parkinson’s disease; chemogenetics; gene therapy; nonhuman primate; retrograde AAV; targeted circuit manipulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Corpus Striatum / metabolism
  • Disease Models, Animal
  • Genetic Therapy*
  • Humans
  • Levodopa / genetics
  • Levodopa / therapeutic use
  • Mice
  • Neurons / metabolism
  • Parkinson Disease* / genetics
  • Parkinson Disease* / therapy
  • Primates
  • Receptors, Dopamine D1 / metabolism

Substances

  • Levodopa
  • Receptors, Dopamine D1